Viktig sikkerhets- og forskrivningsinformasjon

Understand the mechanism of action for OPDIVO^®(nivolumab), YERVOY^®(ipilimumab) and Opdualag^®
 

Opdualag: Fixed-dose combination (FDC) of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3).

Nivolumab: Blocks PD-1 receptor on T-cells, preventing interaction with PD-L1/PD-L2. Restores
T-cell activity and enhances the anti-tumor immune response.

Relatlimab: Targets LAG-3 receptor, reducing its inhibitory effect on T-cells. Further boosts T-cell activity.

Combined effect: Dual blockade of PD-1 and LAG-3 increases T-cell activation more than either antibody alone. Results in reduced tumor growth and enhanced tumor regression in preclinical models.